Every 10-Q that Teladoc Health, Inc. (TDOC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TDOC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDOC filings page.
Teladoc Health, Inc. reported lower revenue and continued losses for the quarter ended June 30, 2026. Revenue was $606,927 (thousands), down from $631,900 (thousands) a year earlier, as growth in the Integrated Care segment only partly offset declines in BetterHelp revenue and paying users.
Net loss for the quarter increased to $38,908 (thousands), while loss from operations narrowed versus the prior year due to reduced advertising, marketing, and overhead spending. Adjusted EBITDA was $65,713 (thousands), slightly below 2025 levels. BetterHelp Paying Users fell 11% to 0.346 million, and management highlighted ongoing pressure from a shift toward insurance-covered services. In Integrated Care, U.S. members declined about 2% to 100.3 million, but chronic care program enrollment rose 14% to 1.272 million. Cash and cash equivalents were $774,348 (thousands), and the company carries $1,000,000 (thousands) of 1.25% convertible senior notes due 2027, now classified as current. A goodwill impairment test for the BetterHelp reporting unit identified no impairment, though management notes that future performance or share-price changes could trigger additional testing.
Teladoc Health reported a narrower loss on slightly lower revenue for the quarter ended March 31, 2026. Revenue was $613.8M, down 2% from $629.4M a year earlier. Access fees fell to $484.7M, while other revenue, including visit fees and device-related sales, rose to $129.2M.
The net loss improved to $63.8M from $93.0M, with basic and diluted loss per share of $0.36 versus $0.53. This improvement mainly reflects the absence of prior-year goodwill impairment and lower operating expenses, partially offset by higher restructuring charges of $12.0M and higher amortization of intangible assets of $89.8M.
Integrated Care revenue grew 2% to $395.4M, while BetterHelp revenue declined to $218.4M as paying users fell 9% to 0.361 million. Adjusted EBITDA was stable at $58.2M. Teladoc ended the quarter with $750.7M in cash and cash equivalents and $1.0B of 1.25% convertible senior notes due 2027, plus an undrawn $300M revolving credit facility.
Teladoc Health (TDOC) reported Q3 2025 results showing revenue of $626.4 million versus $640.5 million a year ago, reflecting softer BetterHelp contributions partly offset by Integrated Care growth. The company posted a net loss of $49.5 million compared with a $33.3 million loss last year, including a $12.6 million goodwill impairment tied to an Integrated Care acquisition.
For the first nine months, revenue was $1.89 billion versus $1.93 billion, with net loss improving to $175.2 million from $952.8 million due to last year’s large goodwill charge. Q3 segment revenue was $389.5 million for Integrated Care and $236.9 million for BetterHelp. Adjusted EBITDA was $69.9 million, down from $83.3 million.
Cash and equivalents were $726.2 million, supported by operating cash flow of $206.6 million year‑to‑date. Teladoc repaid $550.0 million of Livongo 2025 notes and $0.6 million of 2025 notes; $1.0 billion of 2027 notes remain outstanding. The company established a new $300 million revolving credit facility and had $297.8 million available at quarter end.
TDOC Q2 2025 10-Q highlights:
- Revenue slipped 1.6 % YoY to $631.9 m; six-month revenue down 2.1 % to $1.26 bn. U.S. contributed 82 % of sales.
- Losses narrowed sharply. Q2 net loss was $32.7 m (-$0.19/sh) versus -$837.7 m (-$4.92/sh) a year ago, mainly because 2024 contained a $790 m goodwill charge. YTD loss is -$125.7 m (-$0.72/sh) versus -$919.6 m.
- Operating efficiency improved: EBITDA ex-items rose to $69.3 m vs. $89.5 m LY but YTD cash from ops increased to $107.4 m (+10 %). Advertising & marketing trimmed 1.6 %.
- Balance-sheet shifts: Cash fell to $679.6 m from $1.30 bn after $550.6 m retirement of 2025 convertible notes. Only $1 bn 1.25 % 2027 notes remain outstanding. Equity slipped 4.6 % to $1.42 bn; debt-to-equity now 0.70x.
- Intangibles & goodwill: New $59.1 m goodwill from Catapult Health was fully impaired, bringing total YTD impairment to the same amount versus $790 m LY. Intangibles amortization was $88.7 m for the quarter.
- Segment view: Integrated Care revenue +3.7 % YoY while BetterHelp -9.3 %. Integrated Care generated $57.5 m Adjusted EBITDA; BetterHelp $11.9 m.
- Liquidity backstop: On 17 Jul 2025 company executed a new five-year $300 m secured revolving credit facility with variable SOFR+2.75–3.25 % pricing.
Key takeaways: Profitability metrics and cash generation improved despite modest top-line softness, but cash reserves contracted materially after note redemptions and goodwill impairments continue to weigh on equity.